4661-15-8

Usage

Uses

Used in Pharmaceutical Industry:
(4-hydroxy-1-methyl-4-phenylpiperidin-3-yl)(phenyl)methanone hydrochloride (1:1) is used as a psychoactive drug for its powerful and fast-acting analgesic properties. It is particularly effective in cases where other pain relievers are insufficient, providing relief for patients suffering from severe pain.
Used in Medical Field:
In the medical field, (4-hydroxy-1-methyl-4-phenylpiperidin-3-yl)(phenyl)methanone hydrochloride (1:1) is utilized as a pain reliever, offering an alternative to traditional analgesics. Its efficacy in managing pain makes it a crucial component in the treatment of various conditions that cause severe discomfort.
Used in Controlled Substances Regulation:
Due to its potential for abuse and addiction, (4-hydroxy-1-methyl-4-phenylpiperidin-3-yl)(phenyl)methanone hydrochloride (1:1) is also used in the development and implementation of controlled substances regulations. These regulations aim to ensure that the compound is used responsibly and safely, minimizing the risk of misuse and addiction.
Overall, (4-hydroxy-1-methyl-4-phenylpiperidin-3-yl)(phenyl)methanone hydrochloride (1:1) serves as a significant compound in the pharmaceutical and medical industries, providing effective pain relief while also requiring careful oversight to prevent potential harm.

Upstream product

• 103756-12-3 3,3’-(methylazanediyl)bis(1-phenylpropan-1-one) 

Downstream Products

• 768-03-6 Phenyl vinyl ketone 

Relevant academic research and scientific papers

Effect of some bis mannich bases and corresponding piperidinols on DNA topoisomerase I

Some acetophenone (CAS 98-86-2) derived bis Mannich bases, bis-(3-aryl-3-oxo-propyl)-methylamine hydrochlorides (B1-B5) and representative piperidinols, 4-aryl-3-arylcarbonyl-1-methyl-4-piperidinol hydrochlorides (C1, C2 and C5), which are the structural isomers of B1, B2 and B5, were synthesized and their effects on DNA topoisomerase I were tested. Aryl part was phenyl in B1 and C1, p-methyl-phenyl in B2 and C2, p-methoxyphenyl in B3, p-chlorophenyl in B4, and 2-thienyl in B5 and C5. The compounds' chemical structures were confirmed by UV, IR, 1H NMR, 13C NMR, ESI-MS spectra. The purity levels of the compounds were determined by elemental analysis. Among the compounds, B1-B5 and C5 were found to inhibit DNA topo isomerase I at varying degrees. The compounds B1-B5 and C5 manifested an average of 46%, 20%, 40%, 22%, 24% and 22% inhibition on topoisomerase I, respectively, suggesting that the cytotoxic actions of the compounds may be linked to DNA topoisomerase I inhibition. There was a significant negative correlation between the LC 50 values reported and topoisomerase I inhibition among the compounds studied. The topoisomerase inhibiting effects of the compounds of the B series may be attributed to the linear structures of the compounds and the possible formation of the hydrogen bonds with the DNA nucleotides. Among the compounds studied, the most potent topoisomerase I inhibiting compounds B1 (46%) and B3 (40%) may serve as model compounds to develop new more potent topoisomerase inhibitors in future studies. ECV Editio Cantor Verlag.